Semaglutide 7mg tablets: what the evidence says and what UK patients need to know

What the clinical evidence actually shows about oral semaglutide for weight loss

The MHRA approved Wegovy tablets as the UK's first licensed oral GLP-1 medicine for weight management on 11 June 2026, making the UK the first country in Europe to grant that approval. The phase 3 trial behind the decision, OASIS 4, enrolled 307 adults with obesity or overweight alongside at least one weight-related condition, and ran for 64 weeks against a placebo. Average weight loss across all participants, regardless of how consistently they took the tablet, came to around 13.6%, compared with roughly 2.4% on placebo. Among those who stayed fully adherent to treatment throughout, the figure rose to approximately 16.6%. That distinction matters: the higher number is real, but it describes a specific subgroup, not the typical result everyone achieves.

The dose schedule in that trial was 1.5mg to start, escalating through 4mg and 9mg, with 25mg as the maintenance dose, each step separated by at least a month. The 7mg strength you may have seen mentioned online does not appear anywhere in that ladder. It belongs to Rybelsus, where doses run at 3mg, 7mg and 14mg, titrated upward for blood glucose control in people with type 2 diabetes. The two products share an active ingredient, but they are distinct medicines, approved for distinct purposes, under distinct clinical trial programmes. The NHS semaglutide medicines page explains both licences, and it is worth reading if you have seen both brand names mentioned interchangeably.

One practical note about timing: if you are trying to establish a new treatment routine before a holiday or a busy spell at work, the dose-escalation calendar for Wegovy tablets means the full schedule takes several months to complete. Planning that around a Monday order or a quieter period in your diary makes the adjustment easier to manage.

Why the 7mg Rybelsus tablet cannot simply be repurposed for weight loss

Semaglutide works as a GLP-1 receptor agonist, binding to receptors involved in appetite signalling, insulin secretion and gastric emptying. At higher doses, the appetite-suppressing effect becomes more pronounced, which is why weight-loss programmes use larger maintenance doses than the amounts needed to manage blood glucose. Rybelsus at 7mg sits within a diabetes dose range, not a weight-management one.

Prescribing a diabetes medicine for weight loss when a licensed alternative exists is not straightforward. Clinicians follow MHRA-approved indications, and a responsible prescriber will not route a patient toward Rybelsus for weight loss when Wegovy tablets hold that licence. Beyond the regulatory point, the trial data do not support extrapolating Rybelsus outcomes to weight-management goals: the patient populations, treatment durations, and endpoints were different. For a deeper look at how the injection form compares to the tablet, the Wegovy overview covers both formats in the same place.

If you have seen semaglutide 7mg listed on a website alongside claims about weight loss, that is worth treating as a caution rather than an opportunity. The MHRA has been clear that GLP-1 medicines sold without a proper clinical assessment carry real risks, and the dose on the label alone tells you nothing about whether the product is genuine or appropriate for you.

What the Wegovy tablet schedule looks like in practice

The Wegovy weight-loss tablet is taken once daily, first thing in the morning, on an empty stomach with a small amount of plain water, up to around 120ml. Nothing else — no coffee, no food, no other oral medicines — for at least 30 minutes after. It starts at 1.5mg for the first month, moves to 4mg, then 9mg, and reaches 25mg as the intended maintenance dose. Each step requires a minimum of one month before moving on. People already established on the 2.4mg weekly injection may, subject to clinical assessment, move directly to the 25mg tablet rather than repeat the full escalation.

Storage is simpler than the injection: no refrigeration required, which many patients find genuinely useful when travelling or when fridge space is an issue. The most commonly reported side effects in the OASIS 4 trial were gastrointestinal (nausea, diarrhoea, vomiting and constipation) occurring in the majority of participants on active treatment, though most cases were mild to moderate and tended to ease over time. A prescriber will discuss your individual GI history before recommending the tablet over the injection form.

If you are weighing up the injection against the tablet, or wondering whether oral semaglutide suits your circumstances, the weight-loss treatments overview sets out the licensed options clearly. Cost is often part of that consideration too, and the Wegovy pricing page gives factual context on what private treatment typically involves. Semaglutide is a prescription-only medicine; a GPhC-registered prescriber decides which form, if any, is clinically appropriate for you after a proper assessment.

How a clinical assessment separates the right semaglutide product from the wrong one

Both Rybelsus and Wegovy tablets contain semaglutide. That shared active ingredient creates genuine confusion online, and some sellers exploit it. A prescriber's job, in part, is to confirm not just that semaglutide is appropriate but that the right product, dose and indication match the patient sitting in front of them. For weight management, the licensed product is Wegovy; for type 2 diabetes, Rybelsus or Ozempic (the injection form) are the appropriate routes.

At nume, our clinical team includes GPhC-registered Independent Prescribers who read every consultation personally. If the lower dose rungs of the Wegovy schedule are relevant to your situation, or you have questions about how much semaglutide is contained in a standard vial and what that means for your dosing, those are exactly the kinds of clinical questions a prescriber should answer before anything is dispensed. Those considering the 1.7mg Wegovy dose step and what it involves in practice will also find that a useful point to raise during a consultation. The faqs page covers common questions about the process, and if something specific is not answered there, the contact page reaches our team directly. When you are ready to have that conversation, starting a free consultation is the practical next step.